

Emprove[®] Quality Management Dossier

Documentation to support risk assessment

For demonstration purposes only and should not be used for any qualification and/or registration activities.

120079 ESHMUNO®Q

Not appropriate for regulatory submission as active pharmaceutical ingredient. The use of this dossier shall be subject to the terms of use that can be found at **Emprove.de**

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.


Millipore®

Preparation, Separation, Filtration & Testing Products

Table of Contents

If you're viewing this document online, you can click any of the topics below to link directly to that section.

1 Supply Chain Information





2 Product Quality Self-Assessment

	ct Quality Self-Asse sed on Rx360 SAQ Mod relevant for 120079 ESHMUNO® Q		
Merck KGaA, Darmstadt, Germany Corporation with General Pattners Frankforters Yr. 250 04391 Darmstadt, Germany Fronce +49 0151 72-0	Sigma-Aldrich Corporation A subsidiary of Merck KGaA, Darmstadt, Germany 1900 Spince Street St. Louis, MO 61103, USA Photo +1 (800) 521-8956 +1 (314) 771-5765	EMD Millipore Corporation A subidiary of Merck KGaA, Darmstadt, Germany 400 Semait Drive Barlington, MA 1803, USA Phone +1 (781) 533-6000	Page : 1 of 8

	Contents	
١.	General Information	3
П.	Quality Management System (QMS)	3
III.	Documentation Requirements - General	3
IV.	Documentation Requirements - Customer Documentation	3
٧.	Computerized Systems	4
VI.	Personnel Training	4
VII.	Manufacturing Information - Equipment Utilities	4
VIII.	Manufacturing Information - General	5
IX.	Filling Information	6
х.	Environmental Conditions	6
XI.	Labeling / Packaging Information	
XII.	Quality / Laboratory Control	6
XIII.	Sampling	7
XIV.	Materials Management	7
XV.	Revision	

I.	General Information	
1.	This Product Quality Self-Assessment (Product-QSA) provides Quality	
~	Management System information specific to this product.	
2.	This Product-QSA is associated with following documents: a. The Company-wide Self-Assessment for its overall quality system b. The respective Site Quality Self-Assessment (Site-QSA)	
П.	Quality Management System (QMS)	
1.	Are you considered original manufacturer of the listed product ?	New
2.	Which GMP standards are applied for the product?	Rep. 1 - and Ten 1998
III.	Documentation - General	
1.	Is there a conformance statement, quality policy or certificate for GMP requirements ?	transformer statements for
2.	Is there a Certificate of Suitability to the Monographs of the European Pharmacopeia (CEP) for the above-mentioned product ?	-
3.	Is there a Drug Master File (DMF) for the above-mentioned product ?	-
4.	Do you perform annual reports for the aforementioned product ?	-
5.	Is the product EXCIPACT certified ?	-
IV.	Documentation Requirements - Customer Documentation	
1.	If applicable, can you provide the following declarations on request ?	
	a. Aflatoxines b. Allergenes	=
	c. Animal Origin(BSE/TSE)	
	d. cGMP certificate e. GMO	
	f, lonizing Irradiation	=
	g. Manufacturing description / Flowchart	-
	h. Melamine	
	i. Supply Chain Information	-
v.	Computerized Systems	
1.	Are appropriate qualification and validation procedures available for your computerized system ?	-
Merck code	: No.: 120079 15.02.2019	Page :

			l
2.	Do you perform risk assessment for your computerised system ?	-	
3.	Do your computer systems that could impact quality have controls for operation, maintenance and prevention of unauthorised access ?	7	
4.	Do you have an approved master plan of the validation of the computerised system ?	-	
5.	Do you document changes and deviations of validated systems ?	-	
VI.	Personnel - Training		
1.	Are employees working in production rooms given periodic medical check- ups ?	-	
2.	Is it ensured that no person with an infectious disease will come in contact with the product ?	-	
3.	Do you have a job training program ?	-	
4.	Do your training procedures identify training needs by job function ?	1	
5.	Is your personnel trained under GMP requirements ?	-	
6.	Do you have training records and is training completed prior to performing job- relative activities ?	-	
VII.	Manufacturing Information - Equipment Utilities		
1.	Is the product manufactured on dedicated equipment?	-	
		and sugar	
2.	Are there cleaning procedures for non-dedicated equipment to remove the previous product in place?	-	
3.	Has production equipment been qualified?	-	
4.	Has validation been performed for cleaning procedures, as applicable?	-	
5.	If NO to 4., is there data to show that cleaning procedures for non-dedicated equipment is adequate to remove the previous product?	-	
6.	What type of water is involved in manufacturing and cleaning? a. Purified Water / PW (EP and USP grade) b. Highly Purified Water / HPW (EP grade) c. Water for Injection / WFI (EP and USP grade) d. Potable water e. Distilled water	- I	
7.	f. Deionized water What method is used to purify water ? a. Reverse Osmosis b. Ultra-Filtration c. Ion Exchange		
	: No.: 120079 15.02.2019		Page :

		-
8.	Is production performed in aseptic environment ?	
VIII.	Manufacturing Information - General	
1.	If applicable, is production and handling of highly sensitizing materials (such as penicillins or cephalosporins) conducted in closed equipment separate from that used for product manufacture?	-
2.	If applicable, are dedicated production areas or appropriate cleaning activities implemented within the site for material of high pharmacological activity (e.g. certain steroids), toxicity (e.g. cytotoxic anti-cancer agents) or highly toxic non-pharmaceutical materials (e.g. herbicides or pesticides) to avoid cross-contamination ?	-
3.	Is the product manufactured batchwise or continuously ?	And the second sec
4.	How do you define a homogeneous batch ?	from the second
5.	Are solvents excluded from or consistently removed (i.e., to ICH Q3C limits) during the manufacturing process ?	
6.	Are residual solvents reported per ICH Q3C, i.e., listed in the specification and CoA ?	-
7.	Can one batch be traced back to a. its starting material ? b. its IPC (in-process control) ? c. its release control ? d. the bulk material ?	Ē
8.	Do the written procedures cover reprocessing?	national sector read
9.	Are adequate in-process controls performed?	-
10.	Are the in-process controls supervised by the Quality Unit(s)?	-
IX.	Filling Information	
1.	With the respect to the product in question, do you perform filling ?	-
2.	Is there a hygiene monitoring program in the filling area for products manufactured under GMP ?	-
3.	Is there an HVAC system in the filling room/s ?	-
4.	Is filling performed in an aseptic environment ?	
5.	Is the filling line dedicated ?	m patri pre
6.	Is there data to show that cleaning procedures (e.g. cleaning validation) for non-dedicated equipment is adequate to remove the previous product ?	-
Merck code	: No.: 120079 15.02.2019	Page

х.	Environmental Conditions		
1.	Do you monitor and document environmental conditions (e.g. air handling, temperature or sanitary conditions) in the following areas: a. Filling ? b. Finished good warehouse ?	=	
XI.	Labeling/Packaging Information		
1.	Is access to labels and printed materials controlled and recorded ?	-	
2.	Does this include label reconciliation/discarding ?	-	-
3.	Is the original manufacturer name listed on every packaging unit ?	-	
XII.	Quality / Laboratory Control		
1.	Is written information about laboratory instruments available for :		
	a. Qualification instructions and records? b. Calibration instructions and records? c. Maintenance instructions and records? d. Recording, reporting, and storing of raw data?	Ξ	
2.	Do you perform stability studies for the final product ?	-	
3.	Do you perform full testing on your raw materials ?	-	
4.	Is there a reference to compliance to pharmacopoeia given in the product name ?	-	
5.	Which volume of pharmacopoeia is used for lot release ?		
6.	Do you perform all testing listed on the CoA in-house ?	-	
7.	Is the preparation of standards and controls documented ?	-	-
8.	Is there an approved procedure for handling the investigation and documentation of out of specification (OOS) ?	-	
9.	Is there a documented review (double-check) of data by a second individual ?	-	
10.	Is validation of non-compendial analytical procedures a standard requirement for this article ?	-	
XIII.	Sampling		
1.	Do you store and ship samples in the same methods as provided product ?	-	
2.	Do you pull samples in a statistically significant method to provide adequate representation of a product batch ?	-	
Merck code No	x: 120079 15.02.2019		Page : 6

3.	Is the sampling method in your facility validated and/or qualified?		
4.	Do you have suitably equipped sampling areas for the following : a. Incoming goods ? b. Key raw materials ? c. Semi-finished products ? d. Finished products ? e. Packaging materials ? f. Rejected materials?		
xıv.	Materials Management		
1.	Are returnable shipping containers used for this article ?		
2.	If YES to 1., are dedicated Containers used for this article ?		
xv.	Revision		
1.	Content Revision Number		
2.	Template Number	-	
XVI.	Survey Contact Information		
	For further questions, please contact your local sales representative at the office nearest you. For up to date contact information, contact your local business partner		
Merck code	No.: 120079 15.02.2019		Page : 7 of 8


			1
Produ	on provided in response to the ques		ete.
	Quality Services		
This document ha	s been produced electronically and is valid w	ithout a signature.	
Merck code No.: 120079 Merck KGaA, Darmstadt, Germany Corporation with General Patners Frankfarter Str. 250 64293 Darmstad, Germany Phone +09 6151 72-0	15.02.2019 Sigma-Aldrich Corporation A subsidiary of Merck KGaA, Darmstadt, Germany 3050 Sprice Smeet St. Louis, MO 63103, USA Place +1 (800) 521-8956 +1 (314) 771-5765	EMD Millipore Corporation A subsidiary of Morek KGaA, Darmstadt, Germany 400 Surmair Drive Burlington, MA 1803, USA Phone +1 (781) 533-6000	Page : 8 of 8


2019-11-27


3 Supplier and Process Evaluation Statement

Supplier and Process	Evaluation Statem	ent		
We are committed to manufacture materials and a highly specified re excellence. As your supplier of ct analyze all steps in our manufact	nanufacturing process which moice, we have applied a system	neet our requirements for quality matic risk assessment to		
Our risk assessment uses a science-driven and risk-based approach to ensure product quality and patient safety through comprehensive identification, evaluation and mitigation of the risks associated with the listed raw materials and devices. To complete a comprehensive risk assessment we utilize our expertise in research and development, quality control, and manufacturing as well as information from recognized scientific databases and our suppliers.				
This updated Supplier and Proce specific statements:	ss Evaluation is adding further	value to the following product		
 BSE/TSE Risk Assessme Allergen Risk Assessment GMO Risk Assessment Aflatoxin/Mycotoxin Risk / Melamine Risk Assessme 	t Assessment			
Quality Services				
This document has been produce	ed electronically and is valid with	thout a signature.		
Date: 17-Oct-2019				
Merck KGaA Darmstadt, Germany	Sigma Aldrich Corporation	EMD Millipore Corporation		
Corporation with General Partners Frankfurer Str. 250 64293 Darmstaft Phone +49 6151 72-0	A subsidiary of Mesck KGaA, Darmstadt, Germany 3020 Sprace Street St. Louis, MO 63103, U.S.A., Phone +1 (800) 521-8956 (314) 771-5765	A subsidiary of Merck KGaA, Darnsstadt, Germany 400 Semmin Drive Berlington, MA 04803, USA Phone +1 (781) 533-6000		
		Page 1 of 1		

4 Stability data







Millipore®

Preparation, Separation, Filtration & Testing Products

For additional information, please visit

Emprove.de

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

© 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. The vibrant M, Millipore and Emprove are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

VM_ED6023EN 12/2019